ABSTRACT. Angiogenesis and inflammation are closely integrated processes in a number of physiological and pathological conditions, including wound healing, psoriasis, diabetic retinopathy, rheumatoid arthritis, arteriosclerosis, and cancer. Fibroblast growth factor-2 (FGF2) belongs to the family of the heparin-binding FGF growth factors. FGF2 exerts its pro-angiogenic activity by interacting with various endothelial cell surface receptors, including tyrosine kinase receptors, heparan-sulfate proteoglycans, and integrins. Elevated levels of FGF2 have been implicated in the pathogenesis of several diseases characterized by a deregulated angiogenic/inflammatory response. FGF2 induces the expression of a wide repertoire of inflammation-related genes in endothelial cells, including proinflammatory cytokines/chemokines and their receptors, endothelial cell adhesion molecules, and components of the prostaglandin pathway. Consistent with this pro-inflammatory signature, in vivo evidence points to a non-redundant role for chemokines and infiltrating monocytes/macrophages in FGF2-driven neovascularization. This review will focus on the cross-talk between FGF2 and the inflammatory response in the modulation of blood vessel growth.
FGF2 AS AN ANGIOGENIC GROWTH FACTOR
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth [1] . The local, uncontrolled release of angiogenic growth factors and/or alterations in the production of natural angiogenic inhibitors, with a consequent alteration of the angiogenic balance [2] , are responsible for the uncontrolled endothelial cell (EC) proliferation that takes place during tumor neovascularization and in angiogenesisdependent diseases [3] . Angiogenesis is a multi-step process that begins with the degradation of the basement membrane by activated EC that will migrate and proliferate, leading to the formation of solid EC sprouts into the stromal space. Then, vascular loops are formed and capillary tubes develop with formation of tight junctions and deposition of a new basement membrane [4] . Numerous inducers of angiogenesis have been identified, including the members of the vascular endothelial growth factor (VEGF) family, angiopoietins, transforming growth factor-α and -β (TGF-α and -β), platelet-derived growth factor (PDGF), tumor necrosis factor-α (TNF-α), interleukins, chemokines, and members of the fibroblast growth factor (FGF) family.
In 1984, J. Folkman and coworkers discovered a rodent tumor-derived factor able to bind with high affinity to heparin so that it could be purified 200,000-fold by a single passage over a heparin-affinity column. This protein, identified as basic fibroblast growth factor (FGF2), had a molecular weight of 14.8 kD, and stimulated capillary EC proliferation in vitro and angiogenesis in vivo [5, 6] . FGF2 was then purified from human normal cells/tissues [7] and from their transformed counterparts [8] . Purified FGF2 stimulated DNA synthesis, motility, and protease production (urokinase-type plasminogen activator and metalloproteases) in cultured ECs [8] . Also, FGF2 regulates the expression of cadherins, integrins and various extracellular matrix (ECM) components that contribute to the maturation of the new blood vessels regulating lateral cell-cell and substrate adhesions of ECs [9] . In vivo, FGF2 has been shown to induce neovascularization in a variety of animal models, including the chick embryo chorioallantoic membrane (CAM) assay, the rodent cornea assay, the subcutaneous Matrigel plug assay in mice, and the yolk membrane zebrafish embryo (ZFYM) assay [9, 10] . The single copy, human FGF2 gene encodes four coexpressed isoforms (24, 22.5, 22, and 18 kD). The latter isoform is translationally initiated at a classical AUG codon, while the high molecular weight FGF2 isoforms are colinear NH 2 -terminal extensions initiated at novel CUG codons [11] . At variance with other FGFs, FGF2 isoforms lack a leader sequence for secretion and are released in limited amounts by an alternative secretion pathway, via membrane vesicle shedding, or following cell damage [12] . Even though experimental evidence points to significant differences in intracellular and extracellular fate and mechanisms of action of low and high molecular weight FGF2 isoforms [13] , both 24 kD and 18 kD isoforms induce neovascularization in vitro and in vivo [14] . Twenty-three, structurally-related members of the FGF family have been identified [15] . FGFs are pleiotropic factors acting on different cell types, including EC, following interaction with heparan-sulfate proteoglycans (HSPG) and tyrosine kinase FGF receptors (TK-FGFR). Four TK-FGFR have been so far identified, whose structural variability is increased by alternative splicing: FGFR1 (flg), FGFR2 (bek), FGFR3, and FGFR4. They belong to subclass IV of the membrane-spanning receptors [16] and are encoded by distinct genes. All TK-FGFR bind FGF2, with preferential activation of the alternative spliced IIIc form in FGFR 1-3 [17] . FGFR1 [18] , and less frequently FGFR2 [19] are expressed by EC, whereas the expression of FGFR3 or FGFR4 has never been reported in endothelium. FGF2/TK-FGFR interaction causes receptor dimerization and autophosphorylation of specific tyrosine residues located in the intra-cytoplasmic tail of the receptor. This, in turn, leads to complex signal transduction pathways and activation of a "pro-angiogenic phenotype" in EC (reviewed in [9] ). FGF2 can exert its effects on EC via a paracrine mode consequent to its release by tumor and stromal cells and/ or by mobilization from the ECM. On the other hand, FGF2 may also play an autocrine role in EC, as suggested by in vitro and in vivo experimental evidence (see [20] and references therein). Accordingly, FGF2 has been implicated in the pathogenesis of lesions of EC origin, including Kaposi's sarcoma [21] and hemangiomas [22] . To assess the biological consequences of EC activation by endogenous FGF2, we developed a stable mouse aortic EC line transfected with human FGF2 cDNA [20] . FGF2 transfectants show an invasive and morphogenetic behavior in vitro. In vivo, they are angiogenic, cause the formation of opportunistic vascular tumors in nude mice, and induce hemangiomas in the chick embryo [23] . Accordingly, FGF2 transfection affects the expression of numerous genes implicated in the modulation of the cell cycle, differentiation, cell adhesion, and stress/survival [24] . Some of these genes are similarly modulated in vitro and in vivo by administration of the recombinant growth factor [24] . Interestingly, experimental evidence points to different functions of FGF2 isoforms in transfected EC [25] , possibly related to differences in their subcellular localization and release. Indeed, high molecular weight FGF2 isoforms contain a nuclear localization sequence and are mostly recovered in the nucleus, whereas the 18 kDa FGF2 isoform is mostly cytosolic [26] . The constitutive overexpression of high molecular weight FGF2 isoforms leads to cell immortalization, whereas 18 kDa FGF2 overexpression induces a transformed phenotype [27] . Taken together, these data suggest that endogenous FGF2 produced by EC may play important autocrine, intracrine, or paracrine roles in angiogenesis and in the pathogenesis of vascular lesions. In contrast with the potent angiogenic response elicited by exogenous FGF2 in different in vitro and in vivo models, the role of endogenous FGF2 in angiogenesis remains uncertain. Indeed, fgf2-knockout mice are morphologically normal [ 
FGF2/VEGF CROSS-TALK
For many years, FGF2 occupied a central stage in the angiogenesis field. Then, the VEGF family of angiogenic growth factors came into the limelight after the discovery of their pivotal role in vasculogenesis and angiogenesis during embryonic development and under numerous physiological and pathological conditions in adults [33] . The VEGF family comprises six members (VEGF-A denoting the originally identified VEGF) that interact differently with three, cell-surface tyrosine kinase VEGFR. To date, VEGF-A/VEGFR-2 interaction appears to play a major role in blood vessel angiogenesis, whereas VEGF-C and VEGF-D are mainly involved in lymphangiogenesis by interacting with VEGFR-3 expressed on lymphatic endothelium [33] . An intimate cross-talk exists among FGF2 and the different members of the VEGF family during angiogenesis, lymphangiogenesis, and vasculogenesis. There is some experimental evidence that points to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/VEGFR system (see [9] and references therein). On the other hand, EC tube formation, stimulated by VEGF in murine embryonic explants, depends on endogenous FGF2 [34] . Also, FGF2 and VEGF may exert a synergistic effect in different angiogenesis models [35] [36] [37] even though this may not be the case when the two factors are applied onto the chick embryo CAM [38] . Thus, FGF2 may require the activation of the VEGF/FGFR system for promoting angiogenesis. Conversely, VEGF may require FGF2 in order to exert its angiogenic potential under defined experimental conditions. Nevertheless, the two growth factors retain distinct biological properties, exerting different biological effects on EC during angiogenesis [39] [40] [41] [42] [43] . Indeed, using a genetically-modified experimental tumor model, we have observed that FGF2 and VEGF affect tumor blood vessel maturation and functionality differently, with different consequences for tumor oxygenation and viability [41] . Inhibition of FGF2 production resulted in a signifi-cant reduction in tumor size and vascularization that was slightly less efficacious than that caused by the inhibition of VEGF production. Inhibition of both systems caused a further, albeit limited decrease in the rate of tumor growth and angiogenesis. However, none of the treatments was able to fully suppress tumor growth in this model. Other growth factors produced during tumor progression may partially rescue tumorigenicity in the absence of sufficient FGF2 and/or VEGF. Pericytes play a pivotal role in the maturation of newly formed blood vessels. FGF2 causes the recruitment of desmin/NG2-positive pericytes in the chick embryo CAM assay [44] and in the murine subcutaneous Matrigel plug assay [45] . This may be due to a direct effect of FGF2 on mural cells and bone marrow-derived precursors [45] and/or to the ability of FGF2 to induce the expression of platelet-derived growth factor-β and transforming growth factor-β by EC [46] . This, in turn, will affect mural cell behaviour. In this respect, FGF2 and VEGF appear to show a combined effect on the maturation of blood vessels in different experimental settings [47, 48] , with important implications for the angiogenic therapy of ischemic diseases [49, 50] . Interestingly, as observed in tumor vessels, VEGF-induced neovessels are characterized by the presence of endothelial fenestrations, interendothelial junctions and incomplete basement membrane, whereas angiogenesis triggered by FGF2 is not accompanied by these endothelial alterations [51] . Accordingly, inhibition of VEGF activity, but not of FGF2 activity, decreases vascular permeability in experimental tumors [41] , with possible consequence for interstitial pressure, and drug delivery to the neoplastic tissue. The lymphatic system drains extravasated fluid, proteins, and immune cells, and transports them back to the venous circulation via the collecting lymphatic vessels and the thoracic duct. In tumors, the development of the lymphatic network may play a critical role in facilitating the metastatic spread of malignant cells. Recent data demonstrate that FGF/VEGF cross-talk may also occur during lymphangiogenesis. FGF2 pellets implanted in mouse cornea, triggers both angiogenesis and lymphangiogenesis, lymphatic vessels being more sensitive than blood vessels to FGF2 [52] . However, the lymphangiogenic activity of FGF2 is mediated by endogenous VEGF-C and VEGF-D upregulation, leading to VEGFR-3 activation [53]. Interestingly, no endothelial fenestration was observed in FGF2, VEGF-A, or VEGF-C-induced lymphatic vessel [54] . The VEGF/VEGFR system is essential for the development of embryonic vasculature [55] . The situation is much less well-defined for the FGF/FGFR system. As stated above, the phenotype of fgfr knockout mice is not very informative, even though adenovirus-driven, dominant-negative FGFR1 expression leads to severe, vascular alterations in mouse embryos [56] 69] . FGF2 production and release from EC are also triggered by interferon (IFN)-α plus IL-2 [70] , IL-1β [71] , and nitric oxide (NO) [72] . NO is produced by vascular endothelium following stimulation by cytokines, bacterial endotoxins, inflammatory mediators, neuropeptides, and shear stress [73] . Even though FGF2-induced angiogenesis can occur independently of NO synthesis [74] , the pro-angiogenic effects exerted by NO and NO-inducing molecules are due, at least in part, to NO-mediated FGF2 upregulation in EC [75] . Similarly, prostaglandin E 2 -induced angiogenesis is mediated by the activation of EC-surface FGFR1 following mobilization of FGF2 sequestered by the ECM [76] . Thus, inflammatory mediators can activate the endothelium to synthesize and release FGF2 that, in turn, will stimulate angiogenesis by an autocrine mechanism of action. The inflammatory response may also cause cell damage, fluid and plasma protein exudation, and hypoxia. EC damage results in increased FGF2 production and release [77] ; exudated fibrin(ogen) can bind FGF2 and enhance its biological activity [78, 79] ; hypoxia upregulates the production of angiogenic growth factors, including VEGF [80] and FGF2 [63] . Furthermore, hypoxia increases EC responsiveness to FGF2 by promoting HSPG synthesis [81] , and also upregulates FGF2 production in vascular pericytes [82] . On the other hand, the soluble pattern recognition receptor pentraxin 3 (PTX3), synthesized locally by EC in response to IL-1β and TNF-α [83] , binds FGF2 and acts as a natural angiogenesis inhibitor [84, 85] . Also, the heparin-binding C-X-C chemokine platelet factor 4 (PF4), a well known inhibitor of angiogenesis ( [86] and references therein), binds FGF2 [86] and inhibits its interaction with HSPG and FGFR1, internalization and mitogenic activity in EC [86] . Thus, a fine-tuning of the pro-angiogenic activity of FGF2 may occur during inflammation. Conversely, by interacting with EC, FGF2 may amplify the inflammatory and angiogenic response by inducing vasoactive effects and the recruitment of an inflammatory infiltrate. Indeed, FGF2 causes vasodilatation of coronary arterioles via an increase in NO production [87] . FGF2 can also induce vascular permeability directly [88] and indirectly, by upregulating VEGF and proteases. Transient exposure to FGF2 upregulates the expression of the cell adhesion molecules ICAM-1 and VCAM-1 in EC, increasing polymorphonuclear leukocyte adhesion and transendothelial migration [89] . FGF2-stimulated EC upregulate the synthesis of various chemoattractants, including VEGF, (that may exert a chemotactic activity on monocytes [90] ), the angiogenic/ monocyte chemotactic protein osteopontin (Opn) [91] , monocyte chemoattractant protein-1 [42, 92] , and the pro-angiogenic cyclooxygenase-2 (Cox-2) [93] . Moreover, FGF2 exerts a direct chemotactic effect on monocytes (M. Presta, unpublished observations). Finally, in agreement with a possible role of inflammatory cells in FGF2-mediated neovascularization, significant inhibition of the angiogenic response to FGF2 is observed in neutropenic mice [94] . Even though this evidence points to a possible amplification loop of the angiogenic response triggered by FGF2 and mediated by the inflammatory infiltrate, long-lasting exposure to FGF2 down-regulates cytokine-induced ICAM-1, VECAM-1, and E-selectin expression in EC. Consequently, polymorphonuclear leukocyte adhesion and transendothelial migration are reduced [89] . Similarly, monocyte/macrophages adhesion to endothelium, and the chemotactic response to various chemokines are markedly inhibited by long-term stimulation by FGF1 or FGF2, but not by VEGF [95] . Also, FGF2 suppresses transendothelial migration of CD4 + T-lymphocytes [96] and tissue factor expression in EC [97] . These observations suggest that the pro-or anti-inflammatory activity of FGF2 may be contextual and may explain, at least in part, the reduced leukocyte adhesion and transendothelial migration observed in experimental tumors [98] that, nevertheless, are characterized by the presence of proangiogenic tumor-associated macrophages [99] .
FGF2 INDUCES A PRO-INFLAMMATORY SIGNATURE IN ENDOTHELIUM
Taken together, the observations summarized above point to the existence of an intimate cross-talk between inflammatory and angiogenic responses during FGF2-driven neovascularization. In agreement with this hypothesis, gene expression profiling of FGF2-stimulated murine microvascular EC has revealed a pro-inflammatory signature [46] characterized by the upregulation of proinflammatory cytokine/chemokines and their receptors, EC adhesion molecules, and members of the eicosanoid pathway (table 1) . Indeed, FGF2 upregulates the expression of a number of chemokines involved in the recruitment of different inflammatory cells such as monocytes/ macrophages (Ccl2, Ccl7, Cx3cl1, Opn), neutrophils (Cxcl1), NK cells (Cx3cl1) and T lymphocytes (Cxcl16, Cx3cl1 [99] [100] [101] [102] . They can produce pro-angiogenic growth factors (e.g. VEGF, FGF2, IL-1β, IL-8, TNF-α) and proteases [103, 104] . Also, monocytes may contribute to new blood vessel formation by differentiating into endotheliallike cells [105, 106] . Monocytes/macrophages are frequently associated with proliferating blood vessels [107] and can open passages in existing vasculature to facilitate the development of vascular sprouts [104] . Thus, monocytes/macrophages often precede, temporally and spatially, the formation of new vascular sprouts, altering the microenvironment and promoting subsequent EC migration, proliferation, and vessel formation. Accordingly, we have observed that the early recruitment of mononuclear phagocytes (within two-three days after implantation) precedes blood vessel formation in FGF2-driven angiogenesis in the subcutaneous Matrigel plug assay [46] . Indeed, the capacity of monocytes/macrophages to cooperate with EC precursors during FGF2-driven neovascularization in a longterm Matrigel plug assay has been suggested [108] . In addition, numerous F4/80 + cells were observed surrounding the microvessels within the plug, four weeks after implantation. In this study, the authors hypothesize that monocytes/macrophages may contribute to ECM degradation, thus facilitating the invasion of Tie2 + precursors and blood vessel lumen formation. Proper migration of leukocyes to chemotactic agonists in inflammatory sites is dependent upon phosphatidylinositol 3-kinase-γ (PI3Kγ) activity [109, 110] . A significant reduction in the F4/80 + cell infiltrate and in CD31 + neovessels is observed when FGF2-embedded Matrigel plugs are implanted in PI3Kγ -/-mice. Accordingly, macrophage depletion following intraperitoneal pretreatment with clodronate liposomes (Clodrolip) [111, 112] causes a significant reduction in the angiogenic response elicited by FGF2. Thus, monocytes/macrophages play a func-tional, non-redundant early role in FGF2-driven angiogenesis [46] . It is worth noting that the depletion of monocytes/macrophages also reduces the neovascularization driven by VEGF [113, 114] , PIGF [115] , and IL-1β [116] . These data indicate that monocytes/macrophages play a pivotal role in the angiogenesis process driven by various angiogenic growth factors, including FGF2. Moreover, other inflammatory cells, such as polymorphonuclear neutrophils and mast cells, may contribute to pathological angiogenesis [103, 117, 118] . In this respect, corneal neovascularization in response to FGF2 is diminished in neutropenic mice [94] , indicating that different inflammatory cells may sustain FGF2-induced angiogenesis. Further studies are required to elucidate the possible cross-talk between polymorphonuclear neutrophils and monocytes/macrophages in mediating the activity of angiogenic growth factors, including FGF2. It must be pointed out that, together with a proinflammatory signature, FGF2 also upregulates the expression of a variety of angiogenic growth factors in EC, including FGF2 itself and VEGF [46] . This suggests that FGF2 is able to activate an autocrine amplification loop of the angiogenic response that, together with the paracrine activity exerted by endothelium-derived cytokines/chemokines on inflammatory cells, might contribute to the modulation of the neovascularization process triggered by the growth factor. As discussed above, an intimate cross-talk exists between FGF2 and VEGF during angiogenesis. Similarlily to FGF2, VEGF is also known to upregulate the expression of inflammation-related genes in endothelium [119] [120] [121] . However, the two growth factors appear to activate distinct, even though partially overlapping, gene expression profiles in human EC [42] . In our experiments, the induction of inflammation-related genes by FGF2 represents an early event, most of the genes being upregulated one hour after treatment, whereas a limited upregulation of VEGF expression was observed only eight hours after FGF2 stimulation and onward, reaching a two-fold increase in VEGF mRNA levels at 24 hours. These data appear to rule out the possibility that FGF2 may induce a proinflammatory signature in endothelium indirectly via VEGF upregulation. Further experiments are required to fully elucidate the complex interplay between FGF2, VEGF and inflammation during angiogenesis.
FGF2 AS A TARGET FOR ANTI-ANGIOGENIC STRATEGIES
A significant effort has been directed towards the development of anti-angiogenic agents that prevent the growth of new blood vessels, the monoclonal anti-VEGF antibody bevacizumab representing the first FDA approved anti-angiogenic drug [122] . On the other hand, drug resistance to VEGF blockade may occur following reactivation of angiogenesis triggered by compensatory upregulation of the FGF2/TK-FGFR system [123] . Thus, given its potent angiogenic activity, FGF2 may represent the target for the development of novel anti-angiogenic strategies. The various approaches based on the inhibition of FGF2 have been reviewed extensively elsewhere (see [124] and references therein). Briefly, FGF2 can be neutralized at different levels by: i) inhibition of FGF2 production/ release; ii) inhibition of the expression of the various FGF2 receptors in EC (including TK-FGFR, HSPG, gangliosides); iii) engagement by selected antagonists of the various FGF2 receptors (including TK-FGFR, HSPG, gangliosides, and integrins); iv) sequestration of FGF2 in the extracellular environment; v) interruption of the signal transduction pathways triggered by FGF2 in EC. Also, as stated above, FGF2 induces a complex "proangiogenic/pro-inflammatory phenotype" in EC. These processes are mediated by distinct effectors induced/activated by FGF2, and their blockage may result in the inhibition of FGF2-dependent angiogenesis [124] . [125, 126] , with potential therapeutic implications in inflammatory conditions [127] . Our findings suggest that M3 protein may represent the basis for the design of novel angiogenesis inhibitors for therapeutic interventions in angiogenesis-dependent pathological conditions, including tumor growth and metastasis. The bulk of experimental evidence summarized above clearly indicates that the FGF2/TK-FGFR system may represent a target for novel anti-angiogenic strategies in tumors. At present, cancer clinical trials are in progress to assess the safety and efficacy of various compounds with a potential capacity to affect the FGF2/TK-FGFR system at different levels [128, 129] . It must be pointed out however, that the ability to interact with this system may not represent the main rationale that has lead to their testing. This is the case for various heparin derivatives that have been tested in cancer patients because of their antithrombotic effect rather than for their potential FGF2-antagonist activity. Similarly, the humanized monoclonal anti-α v β 3 antibody vitaxin [130, 131] has been investigated for its ability to affect the cell-adhesive function of this integrin receptor rather than its potential ability to act as a signaling TK-FGFR [132] . Also, numerous cytotoxic drugs can affect the FGF2 activity and angiogenesis [124] . Moreover, the impairment of receptors characterized by a broad spectrum of ligands, such as HSPG or integrins, may result in the simultaneous inhibition of various angiogenic growth factors [133] . Novel strategies aimed at inhibiting multiple targets, including FGF2, may represent an effective approach for the treatment of angiogenesisdependent diseases, including cancer.
CONCLUSION
The above observations indicate that FGF2-driven angiogenesis is, at least in part, chemokine-dependent. It is tempting to speculate that chemotactic factors produced by FGF2-stimulated endothelium may recruit mononuclear phagocytes that, in turn, will amplify the angiogenic response by releasing monocyte-derived pro-angiogenic cytokines (figure 2). For instance, Opn, a cytokine endowed with a potent chemoattractant activity for monocytes, is strongly induced by FGF2 in EC [91] . In turn, Opn induces neovascularization [91] by recruiting monocytes/macrophages and promoting the release of the pro-angiogenic cytokine IL-1β [134] . Also, FGF2-induced chemoattractants may play a direct role in neovascularization. Indeed, various chemokines have been shown to function as angiogenic factors by direct interaction with specific chemokine receptors expressed on EC, thus promoting proliferation, migration, and capillary tube formation [135, 136] . Among them, the FGF2-induced chemokines Ccl2, Cxcl1, Cxcl16 and Cxc3l1 could act as enhancers of the neovascularization process elicited by the growth factor. FGF2 expression is increased at sites of chronic inflammation [137] [138] [139] , after tissue injury [140] , and in different types of human cancer [9] . Cell damage, tissue injury and repair, neoplastic transformation, and inflammatory mediators can activate the endothelium, stromal, and parenchymal cells to synthesize and release FGF2 [70] [71] [72] . Released FGF2 may contribute to host defense responses by acting as a danger signal molecule, thus activating pro-angiogenic and pro-inflammatory signatures in endothelium that, by acting in concert, will lead to neovessel formation and monocyte/macrophage engagement ( figure 3) . Indeed, several biological features shown by FGF2 in vitro and in vivo strongly resemble those shown by the chromosomal high mobility group box-1 (HMGB1) protein (summarized in figure 3) , a prototypic, damage-associated molecular pattern (DAMP) cytokine [141] . Interestingly, recent observations from our laboratory have shown the capacity of HMGB1 to trigger angiogenesis by interacting with the receptor for advanced glycation end products (RAGE) expressed by EC [142] . In conclusion, chemokines and inflammatory cells are important early mediators of FGF2-driven angiogenesis and play a relevant role in the neovascularization process elicited by the growth factor. Conversely, FGF2 may exert important functions at sites of inflammation and/or tissue injury, not only by inducing neovascularization but also by contributing to the activation of innate immune responses. sity of Brescia) for the images shown in Figure 1 . Limitation of space preclude extensive citation of the literature; we apologize to those whose work is not mentioned herein. This work was supported by grants from the Istituto Superiore di Sanità 
